BACKGROUND: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV). The cumulative incidence of ADV resistant mutations in the nucleoside/-tide treatment naive chronic hepatitis B patient (CHB) at weeks 48, 96, and 144 was 0, 0.8-3%, and approximately 5.9%, respectively. AIMS: The aim of this study was to characterise the genotypic and phenotypic mutation profiles to ADV in 67 LMV resistant CHB patients who were treated with ADV. METHODS: Serum HBV DNA was quantified by real time polymerase chain reaction. The ADV mutant was detected using matrix assisted laser desorption/ionisation time of flight mass spectrometry based genotyping assays, termed restriction fragment mass polymorphism (RFMP). RESULTS: RFMP analysis revealed that a total of 11 amino acid substitutions developed in the rt domain of the HBV polymerase in nine patients. The cumulative incidence of genotypic ADV resistance at months 12 and 24 was 6.4% and 25.4%, respectively. The rtA181V, rtN236T, and rtA181T mutations were detected in five, four, and two of the 67 patients at treatment months 12-17, 3-19, and 7-20, respectively. Serial quantification of serum HBV DNA revealed that two patients with the rtA181V mutation, with or without the rtN236T mutation, and one patient with the rtA181T mutation displayed HBV DNA rebound. CONCLUSION: Emergence of the ADV mutation in LMV resistant patients who are treated with ADV appeared to present earlier and more frequently than was reported in previous studies on nucleoside/-tide treatment naive patients.
BACKGROUND:Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV). The cumulative incidence of ADV resistant mutations in the nucleoside/-tide treatment naive chronic hepatitis Bpatient (CHB) at weeks 48, 96, and 144 was 0, 0.8-3%, and approximately 5.9%, respectively. AIMS: The aim of this study was to characterise the genotypic and phenotypic mutation profiles to ADV in 67 LMV resistant CHB patients who were treated with ADV. METHODS: Serum HBV DNA was quantified by real time polymerase chain reaction. The ADV mutant was detected using matrix assisted laser desorption/ionisation time of flight mass spectrometry based genotyping assays, termed restriction fragment mass polymorphism (RFMP). RESULTS: RFMP analysis revealed that a total of 11 amino acid substitutions developed in the rt domain of the HBV polymerase in nine patients. The cumulative incidence of genotypic ADV resistance at months 12 and 24 was 6.4% and 25.4%, respectively. The rtA181V, rtN236T, and rtA181T mutations were detected in five, four, and two of the 67 patients at treatment months 12-17, 3-19, and 7-20, respectively. Serial quantification of serum HBV DNA revealed that two patients with the rtA181V mutation, with or without the rtN236T mutation, and one patient with the rtA181T mutation displayed HBV DNA rebound. CONCLUSION: Emergence of the ADV mutation in LMV resistant patients who are treated with ADV appeared to present earlier and more frequently than was reported in previous studies on nucleoside/-tide treatment naive patients.
Authors: Y Benhamou; M Bochet; V Thibault; V Calvez; M H Fievet; P Vig; C S Gibbs; C Brosgart; J Fry; H Namini; C Katlama; T Poynard Journal: Lancet Date: 2001-09-01 Impact factor: 79.321
Authors: D Mutimer; D Pillay; P Cook; D Ratcliffe; K O'Donnell; D Dowling; J Shaw; E Elias; P A Cane Journal: J Infect Dis Date: 2000-02 Impact factor: 5.226
Authors: Patrick Marcellin; Ting-Tsung Chang; Seng Gee Lim; Myron J Tong; William Sievert; Mitchell L Shiffman; Lennox Jeffers; Zachary Goodman; Michael S Wulfsohn; Shelly Xiong; John Fry; Carol L Brosgart Journal: N Engl J Med Date: 2003-02-27 Impact factor: 91.245
Authors: Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary Goodman; Michael S Wulfsohn; Shelly Xiong; John Fry; Carol L Brosgart Journal: N Engl J Med Date: 2003-02-27 Impact factor: 91.245
Authors: Huiling Yang; Christopher E Westland; William E Delaney; Elizabeth J Heathcote; Victoria Ho; John Fry; Carol Brosgart; Craig S Gibbs; Michael D Miller; Shelly Xiong Journal: Hepatology Date: 2002-08 Impact factor: 17.425
Authors: Christopher E Westland; Huiling Yang; William E Delaney; Craig S Gibbs; Michael D Miller; Michael Wulfsohn; John Fry; Carol L Brosgart; Shelly Xiong Journal: Hepatology Date: 2003-07 Impact factor: 17.425
Authors: Eleftherios Michailidis; Karen A Kirby; Atsuko Hachiya; Wangdon Yoo; Sun Pyo Hong; Soo-Ok Kim; William R Folk; Stefan G Sarafianos Journal: Int J Biochem Cell Biol Date: 2012-04-16 Impact factor: 5.085
Authors: Daniel J Tenney; Ronald E Rose; Carl J Baldick; Steven M Levine; Kevin A Pokornowski; Ann W Walsh; Jie Fang; Cheng-Fang Yu; Sharon Zhang; Charles E Mazzucco; Betsy Eggers; Mayla Hsu; Mary Jane Plym; Patricia Poundstone; Joanna Yang; Richard J Colonno Journal: Antimicrob Agents Chemother Date: 2006-12-18 Impact factor: 5.191
Authors: Tae Jung Yun; Jin Yong Jung; Chang Ha Kim; Soon Ho Um; Hyonggin An; Yeon Seok Seo; Jin Dong Kim; Hyung Joon Yim; Bora Keum; Yong Sik Kim; Yoon Tae Jeen; Hong Sik Lee; Hoon Jai Chun; Chang Duck Kim; Ho Sang Ryu Journal: World J Gastroenterol Date: 2012-12-21 Impact factor: 5.742
Authors: Jeong Han Kim; Young Kul Jung; Moon Kyung Joo; Ji Hoon Kim; Hyung Joon Yim; Jong-Jae Park; Jae Seon Kim; Young-Tae Bak; Jong Eun Yeon; Kwan Soo Byun Journal: J Korean Med Sci Date: 2009-01-19 Impact factor: 2.153